Categories: NewsVaccine

Benchling Announces Collaboration with Merck on Vaccine Bioanalysis

Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment

SAN FRANCISCO, June 11, 2025 /PRNewswire/ — Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck’s pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting.

“Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis,” said Sajith Wickramasekara, co-founder and CEO of Benchling. “By focusing on the modern demands of bioanalytical labs, we’re delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle.”

 “Sophisticated data management capabilities are integral to advancing vaccine research and development,” said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. “We’re thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process.”

About Benchling

Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis, and collaboration. With software purpose-built for biology, Benchling is on a mission to unlock the power of biotechnology. To learn more, visit Benchling.com.

View original content:https://www.prnewswire.com/news-releases/benchling-announces-collaboration-with-merck-on-vaccine-bioanalysis-302478378.html

SOURCE Benchling

Staff

Recent Posts

MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - January 7, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a…

2 hours ago

Health In Tech Collaborates with Benefit Re to Launch Over 100 Customized Stop-Loss Self-Funded Healthcare Plans for Employers

Delivers greater program choice for brokers, while offering cost containment service and faster claims processing…

2 hours ago

Lam Research Corporation Announces December Quarter Financial Conference Call

FREMONT, Calif., Jan. 7, 2026 /PRNewswire/ -- Lam Research Corp. (NASDAQ: LRCX) today announced that…

2 hours ago

Vi Releases 2026 State of AI Reports, Defining the New Performance Standard for Healthcare, Biopharma, and Wellness

NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Vi, the AI powering health enterprises that serve…

2 hours ago

OpenAI Selects b.well to Power Secure Health Data Connectivity for AI-Driven Health Experiences in ChatGPT

Partnership enables trusted, consumer-mediated health data access to support more personalized, privacy-first AI health interactionsBALTIMORE…

2 hours ago

Function Launches New App in ChatGPT

Through a First-of-its-kind Integration, Function Members Can Securely Access Health Data Via ChatGPT For Personalized…

2 hours ago